PMID- 22474464
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20211021
IS  - 2092-7258 (Electronic)
IS  - 1738-1061 (Print)
IS  - 1738-1061 (Linking)
VI  - 55
IP  - 3
DP  - 2012 Mar
TI  - Hematopoietic stem cell transplantation in children with acute leukemia: similar 
      outcomes in recipients of umbilical cord blood versus marrow or peripheral blood 
      stem cells from related or unrelated donors.
PG  - 93-9
LID - 10.3345/kjp.2012.55.3.93 [doi]
AB  - PURPOSE: This study compared outcomes in children with acute leukemia who 
      underwent transplantations with umbilical cord blood (UCB), bone marrow, or 
      peripheral blood stem cells from a human leukocyte antigen (HLA)-matched related 
      donor (MRD) or an unrelated donor (URD). METHODS: This retrospective study 
      included consecutive acute leukemia patients who underwent their first allogeneic 
      hematopoietic stem cell transplantation (HSCT) at Samsung Medical Center between 
      2005 and 2010. Patients received stem cells from MRD (n=33), URD (n=46), or UCB 
      (n=41). RESULTS: Neutrophil and platelet recovery were significantly longer after 
      HSCT with UCB than with MRD or URD (P<0.01 for both). In multivariate analysis 
      using the MRD group as a reference, the URD group had a significantly higher risk 
      of grade III to IV acute graft-versus-host disease (GVHD; relative risk [RR], 
      15.2; 95% confidence interval [CI], 1.2 to 186.2; P=0.03) and extensive chronic 
      GVHD (RR, 6.9; 95% CI, 1.9 to 25.2; P<0.01). For all 3 donor types, 5-year 
      event-free survival (EFS) and overall survival were similar. Extensive chronic 
      GVHD was associated with fewer relapses (RR, 0.1; 95% CI, 0.04 to 0.6; P<0.01). 
      Multivariate analysis showed that lower EFS was associated with advanced disease 
      at transplantation (RR, 3.2; 95% CI, 1.3 to 7.8; P<0.01) and total body 
      irradiation (RR, 2.1; 95% CI, 1.0 to 4.3; P=0.04). CONCLUSION: Survival after UCB 
      transplantation was similar to survival after MRD and URD transplantation. For 
      patients lacking an HLA matched donor, the use of UCB is a suitable alternative.
FAU - Yi, Eun Sang
AU  - Yi ES
AD  - Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School 
      of Medicine, Seoul, Korea.
FAU - Lee, Soo Hyun
AU  - Lee SH
FAU - Son, Meong Hi
AU  - Son MH
FAU - Kim, Ju Youn
AU  - Kim JY
FAU - Cho, Eun Joo
AU  - Cho EJ
FAU - Lim, Su Jin
AU  - Lim SJ
FAU - Cheuh, Hee Won
AU  - Cheuh HW
FAU - Yoo, Keon Hee
AU  - Yoo KH
FAU - Sung, Ki Woong
AU  - Sung KW
FAU - Koo, Hong Hoe
AU  - Koo HH
LA  - eng
PT  - Journal Article
DEP - 20120316
PL  - Korea (South)
TA  - Korean J Pediatr
JT  - Korean journal of pediatrics
JID - 101215374
PMC - PMC3315625
OTO - NOTNLM
OT  - Hematopoietic stem cell transplantation
OT  - Stem cell donor
OT  - Umbilical cord blood
EDAT- 2012/04/05 06:00
MHDA- 2012/04/05 06:01
PMCR- 2012/03/01
CRDT- 2012/04/05 06:00
PHST- 2011/09/14 00:00 [received]
PHST- 2011/10/31 00:00 [revised]
PHST- 2011/11/22 00:00 [accepted]
PHST- 2012/04/05 06:00 [entrez]
PHST- 2012/04/05 06:00 [pubmed]
PHST- 2012/04/05 06:01 [medline]
PHST- 2012/03/01 00:00 [pmc-release]
AID - 10.3345/kjp.2012.55.3.93 [doi]
PST - ppublish
SO  - Korean J Pediatr. 2012 Mar;55(3):93-9. doi: 10.3345/kjp.2012.55.3.93. Epub 2012 
      Mar 16.